A detailed history of E Fund Management Co., Ltd. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 6,323 shares of RARE stock, worth $260,191. This represents 0.02% of its overall portfolio holdings.

Number of Shares
6,323
Previous 7,662 17.48%
Holding current value
$260,191
Previous $314,000 11.78%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$40.21 - $59.36 $53,841 - $79,483
-1,339 Reduced 17.48%
6,323 $351,000
Q2 2024

Aug 12, 2024

SELL
$37.42 - $51.61 $34,239 - $47,223
-915 Reduced 10.67%
7,662 $314,000
Q1 2024

May 13, 2024

SELL
$43.02 - $53.69 $141,707 - $176,854
-3,294 Reduced 27.75%
8,577 $400,000
Q4 2023

Feb 06, 2024

BUY
$31.73 - $49.19 $78,277 - $121,351
2,467 Added 26.23%
11,871 $567,000
Q3 2023

Nov 13, 2023

BUY
$34.92 - $46.66 $24,828 - $33,175
711 Added 8.18%
9,404 $335,000
Q2 2023

Aug 11, 2023

SELL
$37.35 - $52.15 $47,471 - $66,282
-1,271 Reduced 12.76%
8,693 $401,000
Q1 2023

May 11, 2023

SELL
$36.99 - $48.71 $16,053 - $21,140
-434 Reduced 4.17%
9,964 $400,000
Q4 2022

Feb 14, 2023

BUY
$33.72 - $46.33 $24,447 - $33,589
725 Added 7.5%
10,398 $482,000
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $35,724 - $59,129
894 Added 10.18%
9,673 $401,000
Q2 2022

Aug 15, 2022

BUY
$45.8 - $85.4 $214,252 - $399,501
4,678 Added 114.07%
8,779 $524,000
Q1 2022

May 12, 2022

BUY
$62.2 - $84.4 $187,159 - $253,959
3,009 Added 275.55%
4,101 $298,000
Q1 2021

May 12, 2021

BUY
$106.9 - $167.73 $116,734 - $183,161
1,092 New
1,092 $124,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.88B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.